GSK PLC (NYSE:GSK)
$ 34.08 -0.04 (-0.12%) Market Cap: 69.61 Bil Enterprise Value: 84.95 Bil PE Ratio: 21.96 PB Ratio: 3.90 GF Score: 71/100

GlaxoSmithKline PLC to Discuss RSV Vaccines Data Investor Call Transcript

Oct 22, 2020 / 01:30PM GMT
Release Date Price: $36.08 (-0.74%)
Unidentified Participant

Good day, everyone, and welcome to GSK's RSV investor call. My name is Deborah, and I'm your event manager. (Operator Instructions) I would like to advise all parties the conference is being recorded.

And now initially, I will hand on to Sarah Elton-Farr, Global Head of Investor Relations. Sarah, please go ahead. Thank you.

Sarah Elton;Farr
GlaxoSmithKline plc - Head of IR

Thank you, Deborah. Good morning and good afternoon. Thank you for joining us to discuss the data presented at ID Week on our RSV vaccine candidates for older adults and maternal immunization. You can access the slides we are going to use in this presentation on the Investors section of GSK's website under Speeches and Presentations.

I would ask you to please review our cautionary statements on Page 2. Also, please note that as we are in close period in our Q3 results next week, we will not be answering any questions on the performance of the business.

And now I'll hand over to Dr. Hal Barron, Chief Scientific Officer and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot